MONTREAL, Nov. 18, 2004 (PRIMEZONE) -- Viropro Pharma, a subsidiary of Viropro Inc. (OTCBB:VPRO) specializing in partnerships and strategic alliances for the marketing and distribution of leading and proven health products in both local and international markets, is pleased to announce an agreement with Miralus Canada Inc. and Miralus International Inc. for the global commercialization of the "FREEdHEM" line of medical products.
Through the new relationship with Miralus International Inc., Viropro Pharma acquires exclusive marketing rights to FREEdHEM for Japan, Central America and South America and non-exclusive rights for most of the countries elsewhere in the world including Canada.
Viropro Pharma President, Mr. Serge Beausoleil commented: "We are extremely pleased about the potential of this new relationship with Miralus Canada Inc. and Miralus International Inc, especially considering that hemorrhoids affect such a large part of the population and that FREEdHEM represents such a unique and effective remedy."
He added, "We are confident about meeting increasing demand which will come from important target markets and we are already working on additional business arrangements to accelerate the marketing and distribution of all medical products in the Viropro portfolio."
The FREEdHEM line of specialized products for the treatment of hemorrhoids surpasses all competitors in that only one application is needed to treat this pervasive ailment which affects 50% of North Americans. FREEdHEM is already available in the United States through retail outlets of large pharmaceutical and food distributors.
On signing the agreement, Mr. Claude Charron, President and Chief Executive Officer of Miralus Canada Inc. and Miralus International Inc stated, "We are highly encouraged by this agreement in that Viropro Pharma is a young and energetic company with a broad international list of public and private contacts. Their relationships in large growing world markets will open new avenues for greater sales volumes and important short-term revenues."
About Viropro
Viropro, Inc. (OTCBB:VPRO) is seeking to establish a growth portfolio in Life Sciences markets through strategic alliances and revenue-producing acquisitions with the potential for continued shareholder value.
About Miralus Canada Inc. and Miralus International Inc
Miralus Canada Inc. and Miralus International Inc are international leaders in R&D, manufacturing and distribution of new generation top quality natural Health products, which are both innovative and unique.
Viropro, Inc's Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward looking statements". Forward looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.